<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03502707</url>
  </required_header>
  <id_info>
    <org_study_id>CR108456</org_study_id>
    <secondary_id>VAC18193RSV1004</secondary_id>
    <nct_id>NCT03502707</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Vaccines &amp; Prevention B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Vaccines &amp; Prevention B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study for:

      Cohort 1 and Cohort 2: to assess the safety and reactogenicity of the intramuscular one- and
      two-dose regimens, with a booster at Month 12 (Cohort 1) and to select a regimen for Cohort
      3.

      Cohort 2 and part of Cohort 1: to assess respiratory syncytial virus (RSV) neutralizing
      antibody levels of the regimens containing RSV pre-fusion (preF) protein compared to the
      one-dose adenovirus serotype 26 respiratory syncytial virus pre-fusion (Ad26.RSV.preF)
      regimen.

      Cohort 3: to assess the safety and reactogenicity of the selected regimen and a booster at
      Month 12.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 6, 2018</start_date>
  <completion_date type="Anticipated">May 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohorts 1, 2, and 3: Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Day 1 until the End of Study (up to 2 years)</time_frame>
    <description>An SAE is an adverse event (AE) resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohorts 1, 2, and 3: Number of Participants With Solicited Local and Systemic AEs for 7 Days After Each Vaccination</measure>
    <time_frame>From Day 1 until 7 days after each vaccination (up to Day 372)</time_frame>
    <description>Solicited AEs are pre-defined local (at the injection site) and systemic events for which participants are specifically questioned and which are noted by participants in their diary. Solicited local AEs: pain/tenderness, induration/swelling and erythema. Solicited systemic AEs: fever, fatigue, headache, myalgia, arthralgia, chills, and nausea. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohorts 1, 2, and 3: Number of Participants With Unsolicited AEs for 28 Days After Each Vaccination</measure>
    <time_frame>From Day 1 until 28 days after each vaccination (up to Day 393)</time_frame>
    <description>Unsolicited AEs are all AEs for which participants are specifically not questioned in the participant diary. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2: Respiratory Syncytial Virus (RSV) A2 Neutralizing Antibody Levels</measure>
    <time_frame>Day 29 (for 1-dose regimen)</time_frame>
    <description>Analysis of RSV A2 neutralizing antibody levels of the vaccine-induced immune response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Respiratory Syncytial Virus (RSV) Neutralization Assays</measure>
    <time_frame>At Day 1 (1st vaccination), Day 15, 29, 57 (2nd vaccination), Day 85, 183, 365 (3rd vaccination), Day 393, 547, 730 or Early Exit (up to 2 years)</time_frame>
    <description>Analysis of neutralizing antibodies to RSV will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts 1 and 2: RSV Fusion Protein (F Protein) Binding Antibodies (Enzyme-Linked Immunosorbent Assay [ELISA]; Pre-Fusion [Pre-F] and/or Post-Fusion [Post-F])</measure>
    <time_frame>At Day 1 (1st vaccination), Day 15, 29, 57 (2nd vaccination), Day 85, 183, 365, Day 393 (Cohort 1 only), Day 547, 730 or Early Exit (up to 2 years)</time_frame>
    <description>Analysis of antibodies binding to RSV F protein in post-fusion (stable conformation) and pre-fusion (metastable conformation) form will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts 1 and 2: Interferon Gamma (IFN-γ) Enzyme-Linked Immunospot (ELISpot) Assay</measure>
    <time_frame>At Day 1 (1st vaccination), Day 15, 29, 57 (2nd vaccination), Day 85, 183, 365, Day 393 (Cohort 1 only), Day 547, 730 or Early Exit (up to 2 years)</time_frame>
    <description>IFN-γ ELISpot assay to assess the RSV F-specific cellular immune responses elicited by the different vaccine regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1 and 2: RSV A2 Neutralizing Antibody Levels</measure>
    <time_frame>At Day 1 (1st vaccination), Day 15, 29, 57 (2nd vaccination), Day 85, 183, 365, Day 393 (Cohort 1 only), Day 547, 730 or Early Exit (up to 2 years)</time_frame>
    <description>Analysis of RSV A2 neutralizing antibody levels of the vaccine-induced immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 3: RSV Neutralization A2 Strain</measure>
    <time_frame>Day 29 (for 1-dose regimen) and Day 85 (for 2-dose regimen)</time_frame>
    <description>Analysis of RSV A2 neutralizing antibody titers of the vaccine-induced immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 3: IFN-γ ELISpot Assay</measure>
    <time_frame>Day 29 (for 1-dose regimen) and Day 85 (for 2-dose regimen)</time_frame>
    <description>IFN-γ ELISpot assay to assess the RSV F-specific cellular immune responses elicited by the selected vaccine regimen.</description>
  </secondary_outcome>
  <number_of_arms>21</number_of_arms>
  <enrollment type="Actual">669</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort (C)1 Group (G)1: Placebo for RSV preF Protein</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G2: RSV preF Protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of 50 microgram (mcg) RSV preF protein on Day 1, Day 57 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G3: Placebo for Ad26.RSV.preF/RSV preF or RSV preF Protein</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G4: Mixture of Ad26.RSV.preF/RSV preF Protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of a mixture of 5*10^10 viral particles (vp) of Ad26.RSV.preF/RSV preF 50 mcg protein on Day 1, Day 57 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G5: RSV preF Protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G6: Mixture of Placebo for Ad26.RSV.preF/RSV preF Protein</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G7: Mixture of Ad26.RSV.preF/RSV preF Protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of a mixture of 5*10^10 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G8: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive intramuscular injection of placebo on Day 1 and at Month 12 and in only 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G9: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of a mixture of 1*10^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and at Month 12 and placebo in another arm on Day 1 and at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive separate intramuscular injections of 1*10^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G11: Ad26.RSV.preF and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of 1*10^11 vp of Ad26.RSV.preF in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G12: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of a mixture of 5*10^10 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G13: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of a mixture of 1*10^11 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G14: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of a mixture of 1*10^11 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G15: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of a mixture of 5*10^10 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Data from C1 G10 will be pooled with those of C2 G16. Participants will receive separate intramuscular injections of 1*10^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and placebo in 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G17: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Data from C1 G9 will be pooled with those of C2 G17. Participants will receive intramuscular injection of a mixture of 1*10^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and placebo in another arm on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G18: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive intramuscular injection of placebo in separate arms on Day 1 and in only 1 arm on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3 G19: Selected Regimen (SR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and a booster (the SR) at Month 12. The participants who are randomized to two-dose regimen will receive SR on Day 1 and Day 57, and a booster (the selected regimen) at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3 G20: SR + Placebo for SR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and a booster (placebo) at Month 12. The participants who are randomized to two-dose regimen will receive selected regimen on Day 1 and Day 57, and a booster (placebo) at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3 G21: Placebo for SR</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>If a one-dose regimen is selected, participants in this group will receive placebo for SR on Day 1 and at Month 12. The participants who are randomized to two-dose regimen will receive placebo for SR on Day 1, Day 57, and Month 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.</description>
    <arm_group_label>C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C1 G3: Placebo for Ad26.RSV.preF/RSV preF or RSV preF Protein</arm_group_label>
    <arm_group_label>C1 G6: Mixture of Placebo for Ad26.RSV.preF/RSV preF Protein</arm_group_label>
    <arm_group_label>C1 G8: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein</arm_group_label>
    <arm_group_label>C1 G9: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G11: Ad26.RSV.preF and Placebo</arm_group_label>
    <arm_group_label>C2 G12: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G13: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G14: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G15: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G17: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G18: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein</arm_group_label>
    <arm_group_label>C3 G20: SR + Placebo for SR</arm_group_label>
    <arm_group_label>C3 G21: Placebo for SR</arm_group_label>
    <arm_group_label>Cohort (C)1 Group (G)1: Placebo for RSV preF Protein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV preF Protein 50 mcg</intervention_name>
    <description>RSV preF will be administered as a solution for intramuscular injection at a dose of 50 mcg.</description>
    <arm_group_label>C1 G2: RSV preF Protein</arm_group_label>
    <other_name>JNJ-64213175</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV preF Protein 150 mcg</intervention_name>
    <description>RSV preF will be administered as a solution for intramuscular injection at a dose of 150 mcg.</description>
    <arm_group_label>C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C1 G5: RSV preF Protein</arm_group_label>
    <arm_group_label>C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <other_name>JNJ-64213175</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.RSV.preF 1*10^11 vp</intervention_name>
    <description>Ad26.RSV.preF will be administered as a solution for intramuscular injection at a dose of 1*10^11 vp.</description>
    <arm_group_label>C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G11: Ad26.RSV.preF and Placebo</arm_group_label>
    <arm_group_label>C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo</arm_group_label>
    <other_name>JNJ-64400141</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg</intervention_name>
    <description>Mixture of Ad26.RSV.preF (5*10^10 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.</description>
    <arm_group_label>C1 G4: Mixture of Ad26.RSV.preF/RSV preF Protein</arm_group_label>
    <arm_group_label>C2 G12: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg</intervention_name>
    <description>Mixture of Ad26.RSV.preF (5*10^10 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.</description>
    <arm_group_label>C1 G7: Mixture of Ad26.RSV.preF/RSV preF Protein</arm_group_label>
    <arm_group_label>C2 G15: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg</intervention_name>
    <description>Mixture of Ad26.RSV.preF (1*10^11 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.</description>
    <arm_group_label>C2 G13: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg</intervention_name>
    <description>Mixture of Ad26.RSV.preF (1*10^11 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.</description>
    <arm_group_label>C1 G9: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G14: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
    <arm_group_label>C2 G17: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Selected Regimen</intervention_name>
    <description>A regimen from Cohort 1 or Cohort 2 will be selected and administered as a solution for intramuscular injection at the selected dose.</description>
    <arm_group_label>C3 G19: Selected Regimen (SR)</arm_group_label>
    <arm_group_label>C3 G20: SR + Placebo for SR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Before randomization, a woman must be postmenopausal (postmenopausal state is defined
             as no menses for 12 months without an alternative medical cause) and not intending to
             conceive by any methods

          -  In the investigator's clinical judgment, participant must be either in good or stable
             health. Participants may have underlying illnesses such as hypertension, type 2
             diabetes mellitus, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms
             and signs are medically controlled. If they are on medication for a condition, the
             medication dose must have been stable for at least 12 weeks preceding vaccination and
             expected to remain stable for the duration of the study. Participants will be included
             on the basis of physical examination, medical history, vital signs, and 12-lead
             electrocardiogram (ECG) performed at screening

          -  For participants in Cohorts 1 and 2 only: Participant must be healthy on the basis of
             clinical laboratory tests performed at screening. If the results of the laboratory
             screening tests are outside the central laboratory normal reference ranges and
             additionally within the limits of toxicity Grade 2 according to the United States (US)
             Food and Drug Administration (FDA) toxicity, the participant may be included only if
             the investigator judges the abnormalities or deviations from normal to be not
             clinically significant and appropriate and reasonable for the population under study.
             This determination must be recorded in the participant's source documents and
             initialed by the investigator

          -  From the time of each vaccination through 3 months after each vaccination, participant
             agrees not to donate blood

          -  Participant must be willing to provide verifiable identification, have means to be
             contacted and to contact the investigator during the study

        Exclusion Criteria:

          -  Per serology testing in Cohorts 1 and 2 and per medical history in Cohort 3:
             Participant has chronic active hepatitis B or hepatitis C infection, documented by
             hepatitis B surface antigen and hepatitis C antibody, respectively

          -  Per serology testing in Cohorts 1 and 2 and per medical history in Cohort 3:
             Participant has human immunodeficiency virus (HIV) type 1 or type 2 infection

          -  Participant has had major psychiatric illness and/or drug or alcohol abuse which in
             the investigator's opinion would compromise the participant's safety and/or compliance
             with the study procedures

          -  Participant has a known allergy, or history of anaphylaxis or other serious adverse
             reactions to vaccines or vaccine components (including any of the constituents of the
             study vaccine)

          -  Participant has received respiratory syncytial virus (RSV) vaccine in a previous RSV
             vaccine study at any time prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Vaccines &amp; Prevention B.V. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Vaccines &amp; Prevention B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108456</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

